Encompass Health (EHC) Earnings Analysis
Encompass Health (EHC) has no confirmed upcoming earnings date. Last quarter (2026-04-30) it beat with EPS 1.6 USD vs 1.51 USD est (+6%). It has beaten estimates in 6/6 recent quarters (100%). Trailing P/E 18.26.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does EHC next report earnings?
No confirmed upcoming earnings date is currently scheduled for EHC. This page updates as the calendar is published.
EHC earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-04-30 | 1.6 USD | 1.51 USD | +6% | Beat |
| 2026-02-05 | 1.46 USD | 1.29 USD | +13.2% | Beat |
| 2025-04-24 | 1.37 USD | 1.19 USD | +15.1% | Beat |
| 2025-02-06 | 1.17 USD | 1.05 USD | +11.4% | Beat |
| 2024-10-28 | 1.03 USD | 0.94 USD | +9.6% | Beat |
| 2024-08-05 | 1.11 USD | 1.01 USD | +9.9% | Beat |
Beat rate: 6/6 (100%) over reported quarters with consensus data.
EHC valuation and analyst view
| Trailing P/E | 18.26 |
|---|---|
| Trailing EPS | 6.141 USD |
| Price / book | 4.37 |
| Dividend yield | 0.68% |
| Market cap | 10.99B |
| Analyst consensus | Buy (21 buy / 4 hold / 1 sell) |
| Avg price target | 146 USD |
Related research pages
Frequently asked questions
When is Encompass Health (EHC)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for EHC. This page updates as the calendar is published.
Did EHC beat earnings last quarter?
In its 2026-04-30 report, EHC posted EPS of 1.6 USD versus a 1.51 USD estimate — a beat of 6%.
What is EHC's earnings track record?
Over the last 6 reported quarters with consensus data, EHC beat estimates 6 times (100%).
What is EHC's current P/E ratio and EPS?
EHC trades at a trailing P/E of 18.26 on trailing EPS of 6.141129032258065 USD.
What do analysts rate EHC?
Analyst consensus is "Buy" across 26 ratings (1 strong buy, 20 buy, 4 hold, 1 sell, 0 strong sell). Average 12-month price target: 146 USD.